Literature DB >> 2695624

Noncompliance with iron chelation therapy in patients with beta thalassaemia.

S Beratis1.   

Abstract

Twenty-three percent of patients with beta thalassaemia were found noncompliant to iron chelation. Excluding separation anxiety disorder and primary functional enuresis, the frequency of psychiatric disorders in the noncompliant and the compliant patients was 68% and 10%, respectively. Oppositional disorder was the most frequent psychiatric disorder; it was also associated with the most profound deviation from compliance. Separation anxiety disorder and primary functional enuresis were not associated with noncompliance. In one-third of the noncompliant patients no psychiatric disorder was identified. School performance was poorer in the noncompliant patients. The presence of psychiatric disorders (mainly oppositional disorder), other than separation anxiety disorder and primary functional enuresis, in thalassaemic patients is a risk factor for noncompliance to treatment. Early identification of noncompliance and appropriate psychiatric intervention may help these patients to become compliant with medical treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2695624     DOI: 10.1016/0022-3999(89)90089-5

Source DB:  PubMed          Journal:  J Psychosom Res        ISSN: 0022-3999            Impact factor:   3.006


  7 in total

1.  Adherence to treatment in adolescents.

Authors:  Danielle Taddeo; Maud Egedy; Jean-Yves Frappier
Journal:  Paediatr Child Health       Date:  2008-01       Impact factor: 2.253

2.  Psychological problems and quality of life in children with thalassemia.

Authors:  D Shaligram; S C Girimaji; S K Chaturvedi
Journal:  Indian J Pediatr       Date:  2007-08       Impact factor: 1.967

3.  Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.

Authors:  Thomas E Delea; Oleg Sofrygin; Simu K Thomas; Jean-Francois Baladi; Pradyumna D Phatak; Thomas D Coates
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  The management of iron chelation therapy: preliminary data from a national registry of thalassaemic patients.

Authors:  Adriana Ceci; Laura Mangiarini; Mariagrazia Felisi; Franco Bartoloni; Angela Ciancio; Marcello Capra; Domenico D'Ascola; Paolo Cianciulli; Aldo Filosa
Journal:  Anemia       Date:  2011-06-05

5.  Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

Authors:  Janet L Kwiatkowski
Journal:  J Blood Med       Date:  2011-09-21

6.  An international survey of patients with thalassemia major and their views about sustaining life-long desferrioxamine use.

Authors:  Alexandra Ward; J Jaime Caro; Traci Craig Green; Krista Huybrechts; Alejandro Arana; Suzanne Wait; Androulla Eleftheriou
Journal:  BMC Clin Pharmacol       Date:  2002-04-23

7.  A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia.

Authors:  Paavani S Reddy; Margaret Locke; Sherif M Badawy
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.